|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 253.80 EUR | -2.20% |
|
-3.61% | +6.45% |
| 07-03 | Berenberg Updates Price Target, Estimates for UCB on Recent Pipeline Deals | MT |
| 06-25 | US prices for new drugs fell in 2025 as fewer costly gene therapies were launched | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 56.51B | |||||
| 66.56B | |||||
| 42.98B | |||||
| 40.46B | - | ||||
| 31.91B | |||||
| 31.65B | - |
- Stock Market
- Stocks
- UCB Stock
- Charts UCB
- Sector Chart
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
